Short Interest in Humacyte, Inc. (NASDAQ:HUMA) Declines By 36.5%

Humacyte, Inc. (NASDAQ:HUMA) saw a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 3,780,000 shares, a decrease of 36.5% from the February 29th total of 5,950,000 shares. Based on an average daily volume of 870,900 shares, the short-interest ratio is presently 4.3 days. Currently, 4.5% of the company’s stock are short sold.

Humacyte Price Performance

NASDAQ:HUMA traded up $0.01 during trading hours on Friday, reaching $3.11. 963,884 shares of the company’s stock were exchanged, compared to its average volume of 1,524,658. The company has a 50-day moving average of $3.55 and a 200 day moving average of $2.98. The company has a quick ratio of 6.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.46. Humacyte has a 1-year low of $1.96 and a 1-year high of $5.60.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. During the same quarter last year, the firm posted ($0.21) EPS. On average, sell-side analysts predict that Humacyte will post -0.94 earnings per share for the current year.

Institutional Trading of Humacyte

A number of large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC lifted its stake in shares of Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after acquiring an additional 6,504 shares during the period. American International Group Inc. acquired a new stake in shares of Humacyte in the 2nd quarter worth $27,000. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of Humacyte in the 4th quarter worth $28,000. Victory Capital Management Inc. acquired a new stake in shares of Humacyte in the 4th quarter worth $29,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Humacyte in the 2nd quarter worth $30,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HUMA. HC Wainwright initiated coverage on shares of Humacyte in a research report on Monday, December 11th. They issued a “buy” rating and a $6.00 price objective on the stock. Piper Sandler restated a “neutral” rating and issued a $4.00 target price on shares of Humacyte in a report on Tuesday. Finally, Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Monday.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).